SEC Form 4 · accession 0000899243-16-014622
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey H Knapp
Officer — Chief Operating Officer
Period of report
Feb 26, 2016
Accepted (ET)
Feb 26, 2016 · 7:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Feb 26, 2016 | A | 5,000 | $0.00 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $16.93 | Feb 26, 2016 | A | 250,000 | A | — | Feb 26, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in full on February 1, 2017.
- F2The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 1, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.